Arch Therapeutics Presents 2014 Milestones During Live Webcast

Arch Therapeutics Presents 2014 Milestones During Live Webcast 
Company Announcement Identifies Pathway to Commercialization and
Added Value Opportunities 
WELLESLEY, MA -- (Marketwired) -- 01/22/14 --  Arch Therapeutics,
Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life sciences company
and developer of the AC5 Surgical Hemostatic Device(TM), a novel
product aimed at controlling bleeding and fluid loss in order to
provide faster and safer surgical and interventional care, is pleased
to announce that Company CEO, Terrence W. Norchi, M.D., presented its
calendar year 2014 milestone targets during a live audio and
high-definition video webcast on Wednesday, January 22 at 10:30AM
Eastern Time from the Noble Financial Capital Markets' Tenth Annual
Equity Conference in South Florida.  
Dr. Norchi advises, "2014 will be an exciting year at Arch
Therapeutics. We are pursuing a series of milestones across all of
our functional activities, including preclinical development,
manufacturing, regulatory, intellectual property, and clinical
development, which we believe will create value for our
shareholders." 
The Company announced the following milestone targets to be completed
before the end of calendar year 2014:  
1. Expand team 
 2. Raise capital 
 3. Select Notified Body for
European regulatory pathway 
 4. Confirm CE mark pathway with
Notified Body 
 5. Select GMP partner for clinical material 
 6.
Complete Clinical Investigational Plan and Ethics Committee approval 
7. Select new pipeline candidate 
 8. Expand intellectual property
portfolio 
 9. Complete manufacturing scale-up for clinical trial  
10. Complete biocompatibility studies on AC5 Surgical Hemostatic
Device(TM) 
 11. Initiate AC5(TM) clinical trial  
A replay of the webcast may be accessed at the following URL:
http://noble.mediasite.com/mediasite/Play/f67c12e0868147e3bc829de48bf213ba1d
or through the Noble Financial websites at: www.noblefcm.com, or
www.nobleresearch.com/TEN/2014.htm. The webcast and presentation will
also be archived on the Arch website for 90 days following the event
at www.archtherapeutics.com. 
About Noble Financial
 Noble Financial Capital Markets was
established in 1984; 2014 marks its 30th Anniversary. Noble Financial
is an equity research driven, full-service, investment banking
boutique focused on life sciences, technology and media, emerging
growth, companies. The company has offices in Boston, Los Angeles,
and Boca Raton, FL. In addition to non-deal road shows and
sector-specific conferences throughout the year, Noble Financial
hosts its large format annual equity conference in January in South
Florida featuring 120 - 150 presenting companies from across North
America and total attendance of close to 600. For more information:
www.noblefcm.com. 
About Arch Therapeutics, Inc. (OTCQB: ARTH)
 Arch Therapeutics, Inc.
is a medical device company developing a novel approach to stop
bleeding (hemostasis) and control leaking (sealant) during surgery
and trauma care. Arch is developing products based on an innovative
self-assembling peptide technology platform to make surgery and
interventional care faster and safer for patients. Arch's flagship
development stage product candidate, known as AC5 Surgical Hemostatic
Device(TM), is being designed to achieve hemostasis in minimally
invasive and open surgical procedures. Find out more at
www.archtherapeutics.com.  
Notice Regarding Forward-Looking Statements
 This news release
contains "forward-looking statements" as that term is defined in
Section 27(a) of the Securities Act of 1933, as amended, and Section
21(e) of the Securities Exchange Act of 1934, as amended. Statements
in this press release that are not purely historical are
forward-looking statements and include any statements regarding
beliefs, plans, expectations or intentions regarding the future. Such
forward-looking statements include, among other things, references to
novel technologies and methods, our business and product development
plans and projections, or market information. Actual results could
differ from those projected in any forward-looking statements due to
numerous factors. Such factors include, among others, the inherent
uncertainties associated with developing new products or technologies
and operating as a development stage company, our ability to retain
important members of our management team and attract other qualified
personnel, our ability to raise the additional funding we will need
to continue to pursue our business and product development plans, our
ability to develop and commercialize products based on our technology
platform, and market conditions. These forward-looking statements are
made as of the date of this news release, and we assume no obligation
to update the forward-looking statements, or to update the reasons
why actual results could differ from those projected in the
forward-looking statements. Although we believe that any beliefs,
plans, expectations and intentions contained in this press release
are reasonable, there can be no assurance that any such beliefs,
plans, expectations or intentions will prove to be accurate.
Investors should consult all of the information set forth herein and
should also refer to the risk factors disclosure outlined in the
reports and other documents we file with the SEC, available at
www.sec.gov. 
On Behalf of the Board,
 Terrence W. Norchi, MD.
 Arch Therapeutics,
Inc. 
Contact:
ARTH Investor Relations
Toll Free: +1-855-340-ARTH (2784) (US and Canada)
Email: investors@archtherapeutics.com 
Website: www.archtherapeutics.com 
 
 
Press spacebar to pause and continue. Press esc to stop.